Cargando…
Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients
The aim of this study was to investigate plasma levels and applicability of CCL2, CCR2, and tumor marker CA 15-3 in breast cancer (BC) patients and in relation to the control groups: patients with benign breast tumor and healthy subjects. Plasma levels of tested parameters were determined by enzyme-...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091289/ https://www.ncbi.nlm.nih.gov/pubmed/30151375 http://dx.doi.org/10.1155/2018/2124390 |
_version_ | 1783347364756455424 |
---|---|
author | Lubowicka, Emilia Przylipiak, Andrzej Zajkowska, Monika Piskór, Barbara Maria Malinowski, Paweł Fiedorowicz, Wojciech Ławicki, Sławomir |
author_facet | Lubowicka, Emilia Przylipiak, Andrzej Zajkowska, Monika Piskór, Barbara Maria Malinowski, Paweł Fiedorowicz, Wojciech Ławicki, Sławomir |
author_sort | Lubowicka, Emilia |
collection | PubMed |
description | The aim of this study was to investigate plasma levels and applicability of CCL2, CCR2, and tumor marker CA 15-3 in breast cancer (BC) patients and in relation to the control groups: patients with benign breast tumor and healthy subjects. Plasma levels of tested parameters were determined by enzyme-linked immunosorbent assay (ELISA) and CA 15-3 by Chemiluminescent Microparticle Immunoassay (CMIA). The median levels of CCL2 in entire group of BC were significantly higher compared to the control groups, similarly as median levels of CA 15-3. CCR2 is a negative marker whose levels were significantly lower in BC group compared to healthy women. The concentration of CCL2 in BC increases with advancing tumor stage, while a median level of CCR2 decreases with advancing stage. CCL2 showed the highest value of sensitivity (SE) (64.95%) in entire BC group and also in early stages of disease. The highest specificity (SP) was obtained by CA 15-3 (85.71%). The area under the ROC curve (AUC) of CCR2 (0.7304) was the largest of all the tested parameters (slightly lower than CA 15-3) in the entire BC group, but a maximum range was obtained for the combination of all tested parameters with CA 15-3 (0.8271). In early stages of BC the highest AUC of all tested parameters was observed in CCL2 or CCR2 (stage I: 0.6604 and 0.6564; respectively; stage II: 0.7768, respectively, for CCR2). The findings of this study suggest that there may be applicability of CCL2, CCR2 in diagnosis of BC patients, particularly in conjunction with CA 15-3. |
format | Online Article Text |
id | pubmed-6091289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-60912892018-08-27 Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients Lubowicka, Emilia Przylipiak, Andrzej Zajkowska, Monika Piskór, Barbara Maria Malinowski, Paweł Fiedorowicz, Wojciech Ławicki, Sławomir Biomed Res Int Research Article The aim of this study was to investigate plasma levels and applicability of CCL2, CCR2, and tumor marker CA 15-3 in breast cancer (BC) patients and in relation to the control groups: patients with benign breast tumor and healthy subjects. Plasma levels of tested parameters were determined by enzyme-linked immunosorbent assay (ELISA) and CA 15-3 by Chemiluminescent Microparticle Immunoassay (CMIA). The median levels of CCL2 in entire group of BC were significantly higher compared to the control groups, similarly as median levels of CA 15-3. CCR2 is a negative marker whose levels were significantly lower in BC group compared to healthy women. The concentration of CCL2 in BC increases with advancing tumor stage, while a median level of CCR2 decreases with advancing stage. CCL2 showed the highest value of sensitivity (SE) (64.95%) in entire BC group and also in early stages of disease. The highest specificity (SP) was obtained by CA 15-3 (85.71%). The area under the ROC curve (AUC) of CCR2 (0.7304) was the largest of all the tested parameters (slightly lower than CA 15-3) in the entire BC group, but a maximum range was obtained for the combination of all tested parameters with CA 15-3 (0.8271). In early stages of BC the highest AUC of all tested parameters was observed in CCL2 or CCR2 (stage I: 0.6604 and 0.6564; respectively; stage II: 0.7768, respectively, for CCR2). The findings of this study suggest that there may be applicability of CCL2, CCR2 in diagnosis of BC patients, particularly in conjunction with CA 15-3. Hindawi 2018-07-30 /pmc/articles/PMC6091289/ /pubmed/30151375 http://dx.doi.org/10.1155/2018/2124390 Text en Copyright © 2018 Emilia Lubowicka et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Lubowicka, Emilia Przylipiak, Andrzej Zajkowska, Monika Piskór, Barbara Maria Malinowski, Paweł Fiedorowicz, Wojciech Ławicki, Sławomir Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients |
title | Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients |
title_full | Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients |
title_fullStr | Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients |
title_full_unstemmed | Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients |
title_short | Plasma Chemokine CCL2 and Its Receptor CCR2 Concentrations as Diagnostic Biomarkers for Breast Cancer Patients |
title_sort | plasma chemokine ccl2 and its receptor ccr2 concentrations as diagnostic biomarkers for breast cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091289/ https://www.ncbi.nlm.nih.gov/pubmed/30151375 http://dx.doi.org/10.1155/2018/2124390 |
work_keys_str_mv | AT lubowickaemilia plasmachemokineccl2anditsreceptorccr2concentrationsasdiagnosticbiomarkersforbreastcancerpatients AT przylipiakandrzej plasmachemokineccl2anditsreceptorccr2concentrationsasdiagnosticbiomarkersforbreastcancerpatients AT zajkowskamonika plasmachemokineccl2anditsreceptorccr2concentrationsasdiagnosticbiomarkersforbreastcancerpatients AT piskorbarbaramaria plasmachemokineccl2anditsreceptorccr2concentrationsasdiagnosticbiomarkersforbreastcancerpatients AT malinowskipaweł plasmachemokineccl2anditsreceptorccr2concentrationsasdiagnosticbiomarkersforbreastcancerpatients AT fiedorowiczwojciech plasmachemokineccl2anditsreceptorccr2concentrationsasdiagnosticbiomarkersforbreastcancerpatients AT ławickisławomir plasmachemokineccl2anditsreceptorccr2concentrationsasdiagnosticbiomarkersforbreastcancerpatients |